Chinese OTC and traditional-Chinese-medicine drugmaker owned by state conglomerate China Resources.
Chinese OTC and traditional-Chinese-medicine drugmaker owned by state conglomerate China Resources.
Sells over-the-counter remedies, mainly cold, stomach and skin products under its 999 brand, through pharmacy chains and wholesalers, so branding and pharmacy shelf presence matter more than doctor prescriptions. China Resources Group's drug-distribution network gives it reach across China. Traditional Chinese medicine granules and prescription drugs are smaller lines.
In one line: A Chinese Bayer Consumer Health for OTC/TCM brands.
Moat: narrow (brand, distribution, scale). Well-known consumer OTC brands and a nationwide pharmacy distribution network under China Resources.
Headquarters: Shenzhen, China · Founded: 1985 · Employees: 30,304
Size China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.59B, the 354th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.40 on 18 Nov 2026.
Performance Over six months the shares gained 5.9%, against -4.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median +16.4%); the operating margin is 13.7% (peer median 14.1%).
Valuation It trades at 13.2× forward earnings against a peer median of 21.6× (5th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -25 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥31.0B | CN¥31.4B | CN¥27.4B | CN¥24.5B | CN¥17.9B |
| Revenue growth | — | +14% | +12% | +37% | — |
| Gross profit | CN¥18.0B | CN¥16.1B | CN¥13.8B | CN¥12.7B | CN¥9.45B |
| EBITDA | n/a | CN¥5.82B | CN¥5.11B | CN¥4.38B | CN¥3.35B |
| Net income | CN¥3.23B | CN¥3.42B | CN¥3.37B | CN¥2.85B | CN¥2.45B |
| Free cash flow | CN¥3.69B | CN¥4.34B | CN¥3.69B | CN¥3.36B | CN¥2.12B |
| Capital expenditure | CN¥1.40B | CN¥1.27B | CN¥790M | CN¥857M | CN¥952M |
| Total debt | CN¥4.94B | CN¥7.31B | CN¥2.26B | CN¥3.94B | CN¥909M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
| Beijing TongRenTang 600085.SS | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% |
| Bayer BAYN.DE | $60.3B | +48% | 0% | 13% | 12.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000999.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.3% | -0.7% | 9th highest of 21 |
| 6-month return | +5.9% | -4.5% | 8th highest of 20 |
| Distance from 52-week high | -13.9% | -25.4% | 8th highest of 21 |
| Revenue growth (TTM) | +4.2% | +16.4% | 5th lowest of 18 |
| Operating margin | 13.7% | 14.1% | 9th lowest of 19 |
| Forward P/E | 13.2× | 21.6× | 5th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -6.2% | 6.6% | 3rd least demanding of 11 |
| Growth delivered (Del g) | +18.4% | +10.7% | 3rd highest of 11 |
| Hurdle (Req g minus delivered) | -24.5 pp | -8.4 pp | 3rd least demanding of 11 |
| ROIC minus cost of capital | +4.4 pp | -0.8 pp | 6th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% | +303.3% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |